Brinson Patrick Starts BioCryst Pharma (BCRX) at Market Outperform

Brinson Patrick initiated coverage on BioCryst Pharma (NASDAQ: BCRX) with a Market Outperform rating and a price target of $15.00.

Analyst Christopher S James said, "Over the next 12-months, we see BioCryst evolving into a leading small molecule, rare disease company. In the nearterm, we remain focused on upcoming data from the Phase IIa OPuS-1 study with BCX4161 in HAE. We believe data from this study will lead to meaningful upside for BCRX shares. Other value drivers include the advancement of two second generation compounds with superior PK, thte PDUFA date for peramivir in 4Q:14, and the advancement of BCX4430."

"BCX4161 is a novel small molecule selective inhibitor of plasma kallikrein, which suppresses bradykinin production, the mediator of angioedema in HAE attacks. HAE is a life threatening, rare genetic disorder that affects 7,000-8,000 patients in the US. With only 3,000-4,000 HAE patients on therapy, and only ~1,000 patients on Cinryze, we see significant room for upside with an oral agent. We expect data from the Phase IIa proof-ofconcept study in Jun. 2014," he added.

For an analyst ratings summary and ratings history on BioCryst Pharma click here. For more ratings news on BioCryst Pharma click here.

Shares of BioCryst Pharma closed at $8.91 yesterday.

You May Also Be Interested In

• BofA Securities Starts GE Vernova (GEV) at Neutral, 'Multiyear turnaround amid positive demand backdrop'
• Cantor Fitzgerald Starts Materialise NV (MTLS) at Overweight, 'Well-Positioned to meet rising software demand'
• Citi Upgrades United Microelectronics Corp (2303:TT) (UMC) to Buy 'with limited downside'